Weight loss drug maker sinks 25% after new safety data spooks investors
—·2d
While the experimental drug met its key targets, analysts are concerned over the commercial opportunity due to side effects.
ChannelsstocksCountriesusaCategoriesanalyst-ratings
Open original source ↗Published
6/8/2026, 11:27:30 AM
Fetched
6/8/2026, 12:07:48 PM
Confidence
60 / 100
Relevance
35 / 100
Trust
—
Language
en